Citadel discloses 4.9% Pliant Therapeutics (PLRX) ownership stake
Rhea-AI Filing Summary
Citadel-affiliated entities and Kenneth Griffin report a significant but sub-5% passive stake in Pliant Therapeutics, Inc. They collectively may be deemed to beneficially own 3,037,695 common shares, equal to 4.9% of the company’s stock, based on 61,449,385 shares outstanding as of November 1, 2025.
The shares are held through Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and related vehicles. All voting and dispositive powers are shared, and the reporting persons certify the holdings were not acquired to change or influence control of Pliant.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake does Citadel report in Pliant Therapeutics (PLRX)?
Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of 3,037,695 Pliant Therapeutics shares, representing 4.9% of the company’s common stock. This percentage is based on 61,449,385 shares outstanding as of November 1, 2025, per Pliant’s Form 10-Q.
Which Citadel entities are included in this Pliant Therapeutics Schedule 13G?
The filing is jointly made by Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin. These reporting persons disclose shared voting and dispositive power over Pliant Therapeutics common shares.
What percentage of Pliant Therapeutics does Kenneth Griffin personally report?
Kenneth Griffin may be deemed to beneficially own 3,037,695 Pliant Therapeutics shares, representing 4.9% of the outstanding common stock. The filing notes he is President and Chief Executive Officer of Citadel GP LLC and owns a controlling interest in Citadel GP LLC and Citadel Securities GP LLC.
Is the Citadel position in Pliant Therapeutics intended to influence control?
The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics. They also state the holdings are not in connection with any transaction having that purpose or effect, other than certain nomination-related activities.
When was the ownership event that triggered this Pliant Therapeutics 13G?
The date of the event requiring this Schedule 13G filing is January 23, 2026. The filing further explains that, except for the share count used for percentage calculations, holdings data are stated as of the opening of the market on January 30, 2026.